Empowering Precision: DoseMeRx Introduces Model-Switch Suggestion and Population Dosing for More Confident, Individualized Therapy
In this article:
Personalized Pharmacokinetic Models Provide Greater Therapy Confidence
Jupiter, FL – May 6, 2025
DoseMe, a leading provider of Bayesian model-informed precision dosing (MIPD), today announced new features for its DoseMeRx platform: Model-Switch Suggestion and Population Dosing Matrix. These tools enhance clinical confidence and accelerate accurate therapy decisions, especially for drugs requiring narrow therapeutic window precision like vancomycin, busulfan, tacrolimus, and warfarin.
Model-Switch Suggestion empowers clinicians to identify alternative pharmacokinetic models that better align with evolving patient data, automatically analyzing model fit. This dynamic tool supplements clinical judgment with real-time data to support more personalized dosing.
Population Dosing Matrix provides actionable insights even before the first drug level is drawn. Using robust population models, it previews potential, initial dosing regimens and predicted AUC24 outcomes, ensuring clinicians can begin therapy with greater clarity and precision.
“These enhancements reinforce our commitment to smarter, safer therapy,” said John Hardesky, Chief Commercial Officer at DoseMe. “By streamlining dosing decisions with real-time intelligence, clinicians can spend more time focused on patient care, not manual calculations.”
Unlike the initial model selection based solely on demographics, Model-Switch Suggestion continuously monitors model performance, working alongside the existing Model Fit Indicator to refine recommendations over time. Institutions may also enable an optional, auditable auto-learning mode for greater flexibility under strict clinical oversight.
“The promise of precision dosing is personalization without complexity,” added Paul Edwards, CEO of DoseMe. “Our new features bring transparency and intelligence to the forefront, driving safer, more effective drug therapy.”
Key Benefits:
- Data-driven model recommendations with continuous reassessment
- Support for first-dose decision-making before lab results
- Improved accuracy and patient safety
- Workflow-friendly tools designed for bedside use
- Transparency and full clinician control over every suggestion
“Clinicians deserve confidence that their dosing models reflect the patient in front of them,” said Sharmeen Roy, PharmD, BCPS, Chief Scientist and Strategy Officer. “These features deliver just that, powerful, research-backed tools that enhance care while keeping decision-making where it belongs: with the clinician.”
For more information about DoseMeRx, visit www.doseme-rx.com.
Additional Resources
Connect with DoseMe on LinkedIn
Follow DoseMe on Twitter
Bookmark the DoseMe Blog
Visit the DoseMe Newsroom
Contact DoseMe
About DoseMe
DoseMe combines smart technology with science, leveraging clinically-validated PK/PD models, patient characteristics, drug concentrations, and genotype to accurately individualize a dose in seconds. The platform is HIPPA complaint and is the only Bayesian dosing platform to be HITRUST CSF R2 certified. For more information on successful applications of its products, DoseMeRx and DoseMe Analytics, visit https://doseme-rx.com/success-stories